Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis

Wang, Yu; Lu, Hongbo; Li, Mi

doi:10.14715/cmb/2022.68.8.13

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 62 PD-L1 and PD-1 are abnormally expressed in the metastatic LNs of T4 stage rectal cancer, and PD-L1 and PD-1 protein expression is more common in patients with T4 stage rectal cancer with LNM than in those without LNM. 63 This pattern demonstrates the potential contribution of PD-L1 derived from non-tumor cells. Therefore, a comprehensive evaluation of PD-L1 expression may be a more accurate approach to predict responses to PD-1/PD-L1 blockade therapy than monitoring PD-L1 expression in tumor cells alone.…”

Section: Challenges Of Ln Removal and Retentionmentioning

confidence: 83%

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Wang,

Zhu,

Shi

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

Tumor-draining lymph nodes (TDLNs) are potential immunotherapy targets that could expand the population of patients with colorectal cancer (CRC) who may benefit from immunotherapy. Currently, pathological detection of tumor cell infiltration limits the acquisition of immune information related to the resected lymph nodes. Understanding the immune function and metastatic risk of specific stages of lymph nodes can facilitate better discussions on the removal or preservation of lymph nodes, as well as the timing of immunotherapy. This review summarized the contribution of TDLNs to CRC responses to immune checkpoint blockade therapy, local immunotherapy, adoptive cell therapy, and cancer vaccines, and discussed the significance of these findings for the development of diagnostics based on TDLNs and the potential implications for guiding immunotherapy after a definitive diagnosis. Molecular pathology and immune spectrum diagnosis of TDLNs will promote significant advances in the selection of immunotherapy options and predicting treatment efficacy.

show abstract

Section: Challenges Of Ln Removal and Retentionmentioning

confidence: 83%

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Wang,

Zhu,

Shi

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…The PD-1/PD-L1 pathway serves as a dual mechanism, providing protection against immune-mediated damage while facilitating tumor cells' evasion of immune attacks. PD-1/PD-L1 has demonstrated promise in various cancer types, including non-small cell lung cancer [1], melanoma [2], renal cell carcinoma [3], and hematological malignancies, such as relapsed/refractory classic Hodgkin lymphoma (HL) [4]. Over recent years, the expression levels of PD-1 or PD-L1 proteins in tumor-infiltrating lymphocytes and tumor cells have emerged as potential biomarkers indicating cancer patients' prognosis [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics

Liang Wang,

Congcong Cao,

Juan Qiu

et al. 2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Molecular pathology and clinical characteristics play a crucial role in guiding treatment selection and predicting the prognosis of diffuse large B-cell lymphoma (DLBCL). The programmed cell death protein 1 (PD-1) and its ligand (PD-L1), have emerged as pivotal regulators of immune checkpoints in cancer. The objectives of this study are to investigate the correlation between the expression levels of PD-1 and soluble PD-L1 (sPD-L1) in the peripheral blood of DLBCL patients, analyze their clinicopathological characteristics, and identify the optimal beneficiary group for PD-1/PD-L1 blockade. Peripheral blood samples were collected from 36 DLBCL patients before their initial treatment at Shandong Cancer Hospital between December 2018 and July 2019. The expression levels of PD-1 and sPD-L1 were measured using flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively. The clinicopathological characteristics, including age, sex, Ann Arbor stage, International Prognostic Index (IPI) score, response to treatment, etc., were recorded for each patient. The surface expression of PD-1 on peripheral blood T cells was significantly higher in DLBCL patients compared to healthy controls. There was a significant association between elevated PD-1 expression levels and the advanced Ann Arbor stage (P=0.0153) as well as the B group (P=0.0184). Higher sPD-L1 levels were associated with the GCB subtype according to Hans's classification (P=0.0435). The expression levels of PD-1 and sPD-L1 in the peripheral blood of DLBCL patients are significantly correlated with advanced disease stage, B group, and GCB subtype according to Hans's classification. This suggests that the PD-1/PD-L1 axis play a critical role in specific subgroups of DLBCL. Targeting this axis could serve as a potential therapeutic strategy to enhance the clinical outcomes of DLBCL patients. Further studies are necessary to explore the prognostic implications of PD-1 and sPD-L1 expression levels in DLBCL patients.

show abstract

Study on the Mechanism and Protection of Salt-Sensitive Hypertensive Rats’ Myocardial Fibrosis by Regulating Striatin with Sacubatrovalsartan

Tu,

Xia,

Chen

et al. 2024

j biomed nanotechnol

View full text Add to dashboard Cite

This study aims to explore the relationship between STRN, TGF-β1, Caspase-3, PD-1 expression, and myocardial fibrosis in salt-sensitive hypertensive rats. It investigates the correlation between STRN expression and myocardial fibrosis, along with the protective effects of Sacubitril/Valsartan (ARNI). Fifteen 18-week-old rats were divided into three groups: Control, high salt (SSH), and ARNI+SSH. Blood pressure was monitored weekly for 8 weeks. Echocardiography evaluated cardiac parameters, while H&E and Masson staining visualized myocardial morphology and fibrosis. Immunohistochemistry measured protein expression of collagen-1, collagen-3, TGF-β1, PD-1, Caspase-3, and STRN. Western blot assessed STRN protein levels. High-salt diet increased fibrosis, collagen expression, TGF-β1, PD-1, Caspase-3, and reduced STRN expression compared to Control (P < 0.05). ARNI treatment decreased fibrosis, collagen expression, TGF-β1, PD-1, Caspase-3 (P <0.05), and increased STRN expression compared to SSH (P <0.05). STRN expression correlated positively with myocardial fibrosis. ARNI demonstrated potential in attenuating fibrosis by modulating STRN expression and suppressing apoptosis and inflammation in salt-sensitive hypertensive rats.

show abstract

Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis

Cited by 3 publications

References 20 publications

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics

Study on the Mechanism and Protection of Salt-Sensitive Hypertensive Rats’ Myocardial Fibrosis by Regulating Striatin with Sacubatrovalsartan

Contact Info

Product

Resources

About